From doit4dale on Stocktwits. Look at what Emma j
Post# of 149993
Chief Executive Officer (CEO) Emma Walmsley said the company lifted its 2031 estimate as the company is "increasing and prioritizing R&D investment to promising new long-acting and specialty medicines in Respiratory, Immunology & Inflammation, Oncology and HIV.”
https://www.investopedia.com/gsk-stock-jumps-...an-8786250
Looks like we might have a few things in common with GSK and their goals.